Compare Huntington Ingalls Industries Inc (HII) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs BIO-TECHNE Corp — how do they compare? Huntington Ingalls Industries Inc trades at $265 (market cap $10.27B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Huntington Ingalls Industries Inc and BIO-TECHNE Corp are close in size by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.12%). Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and BIO-TECHNE Corp for 63 Days on average.
| HII | TECH | |
|---|---|---|
Market Cap | $10.27B | $11.37B |
Volume | 554,386 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $453.73 | $72.61 |
52-Week Low | $257.05 | $43.31 |
Typical Hold Time | 28 Days | 63 Days |
Enterprise Value | $13.19B | $11.40B |
Dividend Yield | 2.12% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $260.67, down 1.17% on the day, amid a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $5.27 exceeding expectations. Recent news highlights contract wins, including a $5.1 billion aircraft carrier overhaul and expansion in unmanned systems, supporting a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.53 and P/S of 0.78.
The outlook is supported by robust defense budgets and contract momentum, but risks include execution on large projects and market sentiment. Analysts are mixed with a 40.7% buy rating and a consensus price target of $363.67, suggesting significant upside potential from current levels if operational performance continues.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
